Researchers reported a number of important findings in lymphoma treatment at the 2019 Annual Meeting of the American Society of Clinical Oncology:

Targeted therapy combination evaluated in treatment of non-germinal center DLBCL

The first-of-its-kind phase II Smart Start trial evaluated a targeted therapy regimen of rituximab, lenalidomide and ibrutinib in the treatment of a specific type of diffuse large B-cell lymphoma (DLBCL).

What Patients Need to Know

Treatment with the targeted therapy regimen resulted in an 84.6 percent overall response rate and a 38.5 percent complete response rate when given, prior to chemotherapy, to newly-diagnosed patients with non-germinal center DLBCL.

No additional benefit shown in rituximab as maintenance treatment in DLBCL

According to the results of a phase II trial, people with diffuse large B-cell lymphoma who achieve complete remission after treatment with R-CHOP received no additional disease-free survival benefit from undergoing maintenance treatment with the immunotherapy rituximab.

What Patients Need to Know

R-CHOP is a regimen that consists of rituximab, the chemotherapies cyclophosphamide, doxorubicin and vincristine and the steroid prednisone.

Phase III trial shows clinical benefit of combination immunotherapy in treatment of FL and MZL

The results of the phase III MAGNIFY trial showed that the immunotherapy combination of lenalidomide plus rituximab demonstrated clinical activity in the treatment of follicular lymphoma (FL) and marginal zone lymphoma (MZL).

What Patients Need to Know

The lenalidomide/rituximab combination produced responses even in people who had previously experienced early relapse (return of their lymphoma) and whose FL or MLZ was refractory (resistant to treatment).

Targeted therapy and immunotherapy combination evaluated in previouslyuntreated CLL

In the treatment of chronic lymphocytic leukemia (CLL), the phase III CLL14 trial compared the targeted therapy venetoclax plus the immunotherapy obinutuzumab with the chemotherapy chlorambucil plus obinutuzumab. The trial participants were people whose CLL had not been previously treated, and who also had comorbidities (other chronic health conditions).

What Patients Need to Know

Researchers concluded that venetoclax plus obinutuzumab induced minimal residual disease (MRD) negativity, resulting in improved progression-free survival. Negative MRD status means that no cancer can be detected, even with the use of sophisticated diagnostic tests.